
New Results on BAY 2927088 for HER2-Mutant NSCLC Presented at WCLC
Bayer has reported promising results from the Phase I/II SOHO-01 study, which is evaluating BAY 2927088 for advanced HER2-mutant non-small cell lung cancer (NSCLC). The data were presented at the IASLC 2024 World Conference on Lung Cancer (WCLC) in San…












